Lead Product(s) : SkinTE
Therapeutic Area : Podiatry
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data show a statistically significant difference favoring PolarityTE’s autologous skin construct, SkinTE, in the primary endpoint of wounds closed at 12 weeks, and in percent area reduction of wounds at each time point measured.
Brand Name : SkinTE
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 24, 2020
Lead Product(s) : SkinTE
Therapeutic Area : Podiatry
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?